Onkologie. 2024:18(4):254-258 | DOI: 10.36290/xon.2024.052

New targets in gastric cancer

Marián Liberko^{1, 2}, Renata Soumarová^{1, 2}

¹ Onkologická klinika, 3. LF UK a FNKV, Praha

² 3. lékařská fakulta Univerzity Karlovy, Praha

Gastric cancer is a heterogeneous disease, both in terms of the frequency of occurrence in individual regions and the frequency of specific molecular alterations that are potentially targetable. In addition to the standard accepted, classical predictive and prognostic biomarkers (Her2, MMR or MSI, PD-L1 CPS) that need to be known prior to therapy, new ones are emerging that have the potential to significantly impact our treatment algorithms and ultimately patient prognosis. The aim of this article is to provide an overview of new potential therapeutic targets (CLDN 18.2, FGFR2b) in the treatment of this disease that, based on the positive results of recent studies, may be introduced into routine clinical practice in the near future.

Keywords: metastatic gastric cancer, FGFR2b, CLDN 18.2, immunotherapy.

Accepted: October 1, 2024; Published: October 7, 2024  Show citation